دورية أكاديمية
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
| العنوان: | Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. |
|---|---|
| المؤلفون: | Rebold N; Wayne State University, Detroit, MI, USA. nicholas.rebold@howard.edu.; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA. nicholas.rebold@howard.edu.; Department of Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, 2300 4th St NW, Office 114, Washington, DC, 20059, USA. nicholas.rebold@howard.edu., Alosaimy S; Wayne State University, Detroit, MI, USA.; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA., Pearson JC; Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA., Dionne B; Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.; School of Pharmacy, Northeastern University, Boston, MA, USA., Taqi A; Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA., Lagnf A; Wayne State University, Detroit, MI, USA.; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA.; Detroit Medical Center, Detroit Receiving Hospital, Detroit, MI, USA., Lucas K; Wayne State University, Detroit, MI, USA.; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA., Biagi M; College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.; Department of Pharmacy, Swedish American Health System, Rockford, IL, USA., Lombardo N; Department of Pharmacy, Swedish American Health System, Rockford, IL, USA., Eudy J; Department of Pharmacy, Augusta University Medical Center, Augusta, GA, USA., Anderson DT; Department of Pharmacy, Augusta University Medical Center, Augusta, GA, USA., Mahoney MV; Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA., Kufel WD; Department of Medicine, State University of New York Upstate Medical University, Syracuse, NY, USA.; Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA., D'Antonio JA; Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA., Jones BM; Department of Pharmacy, St. Joseph's/Candler Health System, Savannah, GA, USA., Frens JJ; Department of Pharmacy, Moses H. Cone Memorial Hospital, Cone Health, Greensboro, NC, USA., Baumeister T; Department of Pharmacy, Moses H. Cone Memorial Hospital, Cone Health, Greensboro, NC, USA., Geriak M; Sharp Memorial Hospital, Sharp Healthcare, San Diego, CA, USA., Sakoulas G; Sharp Rees-Stealy Medical Group, San Diego, CA, USA.; University of California San Diego School of Medicine, Division of Host-Microbe Systems and Therapeutics, La Jolla, CA, USA., Farmakiotis D; Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA.; Transplant and Oncology Infectious Diseases, Rhode Island Hospital, Providence, RI, USA., Delaportas D; Mon Health Medical Center, Morgantown, WV, USA., Larew J; Mon Health Medical Center, Morgantown, WV, USA., Veve MP; Wayne State University, Detroit, MI, USA.; College of Pharmacy, University of Tennessee, Knoxville, TN, USA.; Department of Pharmacy, Henry Ford Health System, Detroit, MI, USA., Rybak MJ; Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA. m.rybak@wayne.edu.; Detroit Medical Center, Detroit Receiving Hospital, Detroit, MI, USA. m.rybak@wayne.edu.; School of Medicine, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu. |
| المصدر: | Infectious diseases and therapy [Infect Dis Ther] 2024 Mar; Vol. 13 (3), pp. 565-579. Date of Electronic Publication: 2024 Mar 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : [Auckland] Adis Original Publication: [London] : Springer Healthcare |
| مستخلص: | Introduction: Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed to provide further multicenter real-world evidence on dalbavancin use as a sequential therapy for Gram-positive BSI. Methods: One hundred fifteen patients received dalbavancin with Gram-positive BSI, defined as any positive blood culture or diagnosed with infective endocarditis, from 13 centers geographically spread across the United States between July 2015 and July 2021. Results: Patients had a mean (SD) age of 48.5 (17.5) years, the majority were male (54%), with many who injected drugs (40%). The most common infection sources (non-exclusive) were primary BSI (89%), skin and soft tissue infection (SSTI) (25%), infective endocarditis (19%), and bone and joint infection (17%). Staphylococcus aureus accounted for 72% of index cultures, coagulase-negative Staphylococcus accounted for 18%, and Streptococcus species in 16%. Dalbavancin started a median (Q Conclusions: Dalbavancin may serve as a useful tool in facilitating hospital discharge in patients with Gram-positive BSI. Randomized controlled trials are anticipated to validate dalbavancin as a surrogate to current treatment standards. (© 2024. The Author(s).) |
| References: | Cooper GL, Given DB. Vancomycin: a comprehensive review of 30 years of clinical experience. Park Row Publishing Incorporated A Wiley and Sons Medical Group Comp; 1986. Ramos-Otero GP, Sarangarm P, Walraven C. A retrospective analysis of intravenous vs oral antibiotic step-down therapy for the treatment of uncomplicated streptococcal bloodstream infections. J Clin Pharmacol. 2022. https://doi.org/10.1002/jcph.2097 . (PMID: 10.1002/jcph.209735661173) Al-Hasan MN, Rac H. Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections. Clin Microbiol Infect. 2020;26(3):299–306. (PMID: 10.1016/j.cmi.2019.05.01231128289) Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425–36. (PMID: 10.1056/NEJMoa1710926306993156522347) Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N England J Med. 2019. https://doi.org/10.1056/NEJMoa1808312 . (PMID: 10.1056/NEJMoa1808312) Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotherapy. 2020;40(5):469–78. (PMID: 10.1002/phar.238932239771) Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361–8. (PMID: 10.1016/j.cmi.2017.08.02828882727) Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79. (PMID: 10.1056/NEJMoa131048024897082) Bryson-Cahn C, Beieler A, Chan J, Senter S, Harrington R, Dhanireddy S. A little bit of dalba goes a long way: dalbavancin use in a vulnerable patient population. Open Forum Inf Dis. 2017;4(1):336–7. (PMID: 10.1093/ofid/ofx163.800) Gatti M, Andreoni M, Pea F, Viale P. real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs . DDDT. 2021;15:3349–78. (PMID: 10.2147/DDDT.S313756343769718349200)Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Outcomes in patients with Staphylococcus aureus bacteremia treated with dalbavancin in clinical trials. Infect Dis Ther. 2022;11(1):423–34. (PMID: 10.1007/s40121-021-00568-734905144) Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–4. (PMID: 10.1016/j.ijid.2019.02.01330794940) Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18:30. (PMID: 10.1186/s12941-019-0329-6316294096800500) Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Inf Dis. 2019. https://doi.org/10.1093/ofid/ofy331 . (PMID: 10.1093/ofid/ofy331) Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard of care for outpatient treatment of invasive Gram-positive infections. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.106210 . (PMID: 10.1016/j.ijantimicag.2020.10621033223119) Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018;67(5):795–8. (PMID: 10.1093/cid/ciy27929659732) Antosz K, Al-Hasan MN, Lu ZK, et al. Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care. Pharmacy. 2022;10(1):1. (PMID: 10.3390/pharmacy10010001) Molina KC, Lunowa C, Lebin M, et al. Comparison of sequential dalbavancin to standard-of-care treatment for Staphylococcus aureus bloodstream infections. Open Forum Inf Dis. 2022. https://doi.org/10.1093/ofid/ofac335 . (PMID: 10.1093/ofid/ofac335) Evins C, Lancaster H, Schnee AE. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series. Ann Clin Microbiol Antimicrob. 2022;21:16. (PMID: 10.1186/s12941-022-00507-5354737119044886) Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374–80. (PMID: 10.1086/42728315668859) AbbVie (2022) Phase 2, Open-label, randomized, multicenter study to compare the efficacy and safety of dalbavancin to standard of care antibiotic therapy for the completion of treatment of patients with complicated bacteremia or documented infective endocarditis. clinicaltrials.gov. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–55. (PMID: 10.1128/AAC.04550-14255613384356775) Cojutti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with Staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2021;65(5):e02260-e2320. (PMID: 10.1128/AAC.02260-20336491088092885) Baklouti S, Marolleau S, Chavanet P, Bonnet E, Concordet, Gandia P (2021) Letter to the Editor on: “Population pharmacokinetics of dalbavancin and dosing considerations for optimal treatment of adult patients with Staphylococcal osteoarticular Infections”. Antimicrob Agents Chemother. Published online October 18, 2021:AAC.01493-21. Cooper MM, Preslaski CR, Shihadeh KC, Hawkins KL, Jenkins TC. Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review. Open Forum Inf Dis. 2021. https://doi.org/10.1093/ofid/ofab486 . (PMID: 10.1093/ofid/ofab486) Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55. (PMID: 10.1093/cid/ciq14621208910) Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. (PMID: 10.1016/j.jbi.2008.08.01018929686) Eaton EF, Westfall AO, McClesky B, et al. In-hospital illicit drug use and patient-directed discharge: barriers to care for patients with injection-related infections. Open Forum Inf Dis. 2020;7(3):074. Turner NA, Zaharoff S, King H, et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022;23:407. (PMID: 10.1186/s13063-022-06370-1355783609109297) National Institute of Allergy and Infectious Diseases (NIAID) (2021) Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): a phase 2b, multicenter, randomized, open-label, assessor-blinded superiority study to compare the efficacy and safety of dalbavancin to standard of care antibiotic therapy for the completion of treatment of patients with complicated S. aureus Bacteremia. clinicaltrials.gov. Steele JM, Seabury RW, Hale CM, Mogle BT. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. J Clin Pharm Ther. 2018;43(1):101–3. (PMID: 10.1111/jcpt.1258028628223) Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018;24(4):429.e1-429.e5. (PMID: 10.1016/j.cmi.2017.07.02828782651) Kussmann M, Karer M, Obermueller M, et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018;7:202. (PMID: 10.1038/s41426-018-0205-z305149236279813) Zhang R, Polenakovik H, Barreras Beltran IA, et al. Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization. Clinl Inf Dis. 2022. https://doi.org/10.1093/cid/ciac341 . (PMID: 10.1093/cid/ciac341) |
| فهرسة مساهمة: | Keywords: Staphylococcus; Streptococcus; Bacteremia; Bloodstream infection; Dalbavancin; Glycopeptides; Injection drug use |
| تواريخ الأحداث: | Date Created: 20240301 Latest Revision: 20240813 |
| رمز التحديث: | 20240813 |
| مُعرف محوري في PubMed: | PMC10965835 |
| DOI: | 10.1007/s40121-024-00933-2 |
| PMID: | 38427289 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2193-8229 |
|---|---|
| DOI: | 10.1007/s40121-024-00933-2 |